Skip to main content
Erschienen in: Tumor Biology 10/2016

05.09.2016 | Original Article

FBXO25 promotes cell proliferation, invasion, and migration of NSCLC

verfasst von: Gui-Yang Jiang, Xiu-Peng Zhang, Liang Wang, Xu-Yong Lin, Juan-Han Yu, En-Hua Wang, Yong Zhang

Erschienen in: Tumor Biology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

FBXO25 is a recently discovered protein that belongs to the Fbx class of the F-box family of proteins, and F-box proteins play a crucial role in tumorigenesis. However, the function of FBXO25 in cancer was not revealed so far. As measured by immunohistochemical staining, FBXO25 was highly expressed in the cytoplasm and nucleus of lung cancer samples (64.2 %, 136/212), compared with adjacent normal lung tissues (23.3 %, 7/30, p < 0.01). In addition, its expression was positively correlated with TNM staging (p < 0.001) and lymph node metastasis (p = 0.017). The overall survival of non-small-cell lung cancer (NSCLC) patients with FBXO25-positive expression (40.646 ± 1.745 months) was significantly reduced compared with those with FBXO25-negative expression (46.548 ± 2.176 months, p = 0.023). Consistently, we found that the proliferation, invasion, and migration capacity of A549 cells transfected with FBXO25 were significantly greater than those of control cells, while interference of FBXO25 could significantly inhibit cell proliferation, invasion, and migration in H1299 cells. Furthermore, we demonstrated that FBXO25 could regulate the expression of β-catenin, YAP, some cyclins, and matrix metalloproteinases (MMPs). Collectively, these results indicate that FBXO25 may promote the tumorigenicity of lung cancer cells and might serve as a novel therapeutic target of NSCLC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bassermann F, Eichner R, Pagano M. The ubiquitin proteasome system—implications for cell cycle control and the targeted treatment of cancer. Biochim Biophys Acta. 2014;1843:150–62.CrossRefPubMed Bassermann F, Eichner R, Pagano M. The ubiquitin proteasome system—implications for cell cycle control and the targeted treatment of cancer. Biochim Biophys Acta. 2014;1843:150–62.CrossRefPubMed
2.
Zurück zum Zitat Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2011;10:29–46.CrossRefPubMed Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2011;10:29–46.CrossRefPubMed
3.
Zurück zum Zitat Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M. Identification of a family of human f-box proteins. Current biology: CB. 1999;9:1177–9.CrossRefPubMed Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M. Identification of a family of human f-box proteins. Current biology: CB. 1999;9:1177–9.CrossRefPubMed
4.
Zurück zum Zitat Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW. A family of mammalian f-box proteins. Current biology: CB. 1999;9:1180–2.CrossRefPubMed Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW. A family of mammalian f-box proteins. Current biology: CB. 1999;9:1180–2.CrossRefPubMed
5.
Zurück zum Zitat Zheng N, Wang Z, Wei W. Ubiquitination-mediated degradation of cell cycle-related proteins by f-box proteins. Int J Biochem Cell Biol. 2016;73:99–110.CrossRefPubMed Zheng N, Wang Z, Wei W. Ubiquitination-mediated degradation of cell cycle-related proteins by f-box proteins. Int J Biochem Cell Biol. 2016;73:99–110.CrossRefPubMed
6.
Zurück zum Zitat Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS. F-box proteins in cancer cachexia and muscle wasting: emerging regulators and therapeutic opportunities. Semin Cancer Biol. 2016;36:95–104.CrossRefPubMed Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS. F-box proteins in cancer cachexia and muscle wasting: emerging regulators and therapeutic opportunities. Semin Cancer Biol. 2016;36:95–104.CrossRefPubMed
7.
Zurück zum Zitat Bochis OV, Fetica B, Vlad C, Achimas-Cadariu P, Irimie A. The importance of ubiquitin e3 ligases, scf and apc/c, in human cancers. Clujul medical. 2015;88:9–14.CrossRefPubMedPubMedCentral Bochis OV, Fetica B, Vlad C, Achimas-Cadariu P, Irimie A. The importance of ubiquitin e3 ligases, scf and apc/c, in human cancers. Clujul medical. 2015;88:9–14.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Heo J, Eki R, Abbas T. Deregulation of f-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol. 2016;36:33–51.CrossRefPubMed Heo J, Eki R, Abbas T. Deregulation of f-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol. 2016;36:33–51.CrossRefPubMed
9.
Zurück zum Zitat Liu Y, Mallampalli RK. Small molecule therapeutics targeting f-box proteins in cancer. Semin Cancer Biol. 2016;36:105–19.CrossRefPubMed Liu Y, Mallampalli RK. Small molecule therapeutics targeting f-box proteins in cancer. Semin Cancer Biol. 2016;36:105–19.CrossRefPubMed
10.
Zurück zum Zitat Uddin S, Bhat AA, Krishnankutty R, Mir F, Kulinski M, Mohammad RM. Involvement of f-box proteins in progression and development of human malignancies. Semin Cancer Biol. 2016;36:18–32.CrossRefPubMed Uddin S, Bhat AA, Krishnankutty R, Mir F, Kulinski M, Mohammad RM. Involvement of f-box proteins in progression and development of human malignancies. Semin Cancer Biol. 2016;36:18–32.CrossRefPubMed
11.
Zurück zum Zitat Hagens O, Minina E, Schweiger S, Ropers HH, Kalscheuer V. Characterization of fbx25, encoding a novel brain-expressed f-box protein. Biochim Biophys Acta. 2006;1760:110–8.CrossRefPubMed Hagens O, Minina E, Schweiger S, Ropers HH, Kalscheuer V. Characterization of fbx25, encoding a novel brain-expressed f-box protein. Biochim Biophys Acta. 2006;1760:110–8.CrossRefPubMed
12.
Zurück zum Zitat Maragno AL, Baqui MM, Gomes MD. Fbxo25, an f-box protein homologue of atrogin-1, is not induced in atrophying muscle. Biochim Biophys Acta. 2006;1760:966–72.CrossRefPubMed Maragno AL, Baqui MM, Gomes MD. Fbxo25, an f-box protein homologue of atrogin-1, is not induced in atrophying muscle. Biochim Biophys Acta. 2006;1760:966–72.CrossRefPubMed
13.
Zurück zum Zitat Teixeira FR, Manfiolli AO, Soares CS, Baqui MM, Koide T, Gomes MD. The f-box protein fbxo25 promotes the proteasome-dependent degradation of elk-1 protein. J Biol Chem. 2013;288:28152–62.CrossRefPubMedPubMedCentral Teixeira FR, Manfiolli AO, Soares CS, Baqui MM, Koide T, Gomes MD. The f-box protein fbxo25 promotes the proteasome-dependent degradation of elk-1 protein. J Biol Chem. 2013;288:28152–62.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Jang JW, Lee WY, Lee JH, Moon SH, Kim CH, Chung HM. A novel fbxo25 acts as an e3 ligase for destructing cardiac specific transcription factors. Biochem Biophys Res Commun. 2011;410:183–8.CrossRefPubMed Jang JW, Lee WY, Lee JH, Moon SH, Kim CH, Chung HM. A novel fbxo25 acts as an e3 ligase for destructing cardiac specific transcription factors. Biochem Biophys Res Commun. 2011;410:183–8.CrossRefPubMed
15.
Zurück zum Zitat Jeong HS, Jung ES, Sim YJ, Kim SJ, Jang JW, Hong KS, Lee WY, Chung HM, Park KT, Jung YS, Kim CH, Kim KS. Fbxo25 controls tbx5 and nkx2-5 transcriptional activity to regulate cardiomyocyte development. Biochim Biophys Acta. 2015;1849:709–21.CrossRefPubMed Jeong HS, Jung ES, Sim YJ, Kim SJ, Jang JW, Hong KS, Lee WY, Chung HM, Park KT, Jung YS, Kim CH, Kim KS. Fbxo25 controls tbx5 and nkx2-5 transcriptional activity to regulate cardiomyocyte development. Biochim Biophys Acta. 2015;1849:709–21.CrossRefPubMed
16.
Zurück zum Zitat Baumann U, Fernandez-Saiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F. Disruption of the prkcd-fbxo25-hax-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nat Med. 2014;20:1401–9.CrossRefPubMed Baumann U, Fernandez-Saiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F. Disruption of the prkcd-fbxo25-hax-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nat Med. 2014;20:1401–9.CrossRefPubMed
17.
Zurück zum Zitat Kang G, Yun H, Sun CH, Park I, Lee S, Kwon J, Do I, Hong ME, Vrancken MV, Lee J, Park JO, Cho J, Kim KM, Sohn TS. Integrated genomic analyses identify frequent gene fusion events and vhl inactivation in gastrointestinal stromal tumors. Oncotarget. 2015;7(6):6538–51.PubMedCentral Kang G, Yun H, Sun CH, Park I, Lee S, Kwon J, Do I, Hong ME, Vrancken MV, Lee J, Park JO, Cho J, Kim KM, Sohn TS. Integrated genomic analyses identify frequent gene fusion events and vhl inactivation in gastrointestinal stromal tumors. Oncotarget. 2015;7(6):6538–51.PubMedCentral
18.
Zurück zum Zitat Frescas D, Pagano M. Deregulated proteolysis by the f-box proteins skp2 and beta-trcp: tipping the scales of cancer. Nature reviews. Cancer. 2008;8:438–49.PubMedPubMedCentral Frescas D, Pagano M. Deregulated proteolysis by the f-box proteins skp2 and beta-trcp: tipping the scales of cancer. Nature reviews. Cancer. 2008;8:438–49.PubMedPubMedCentral
19.
Zurück zum Zitat Fuchs SY, Spiegelman VS, Kumar KG. The many faces of beta-trcp e3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene. 2004;23:2028–36.CrossRefPubMed Fuchs SY, Spiegelman VS, Kumar KG. The many faces of beta-trcp e3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene. 2004;23:2028–36.CrossRefPubMed
20.
Zurück zum Zitat Ougolkov A, Zhang B, Yamashita K, Bilim V, Mai M, Fuchs SY, Minamoto T. Associations among beta-trcp, an e3 ubiquitin ligase receptor, beta-catenin, and nf-kappab in colorectal cancer. J Natl Cancer Inst. 2004;96:1161–70.CrossRefPubMed Ougolkov A, Zhang B, Yamashita K, Bilim V, Mai M, Fuchs SY, Minamoto T. Associations among beta-trcp, an e3 ubiquitin ligase receptor, beta-catenin, and nf-kappab in colorectal cancer. J Natl Cancer Inst. 2004;96:1161–70.CrossRefPubMed
21.
Zurück zum Zitat Koch A, Waha A, Hartmann W, Hrychyk A, Schuller U, Waha A, Wharton KA, Jr., Fuchs SY, von Schweinitz D, Pietsch T: Elevated expression of wnt antagonists is a common event in hepatoblastomas. Clinical cancer research: an official journal of the American Association for Cancer Research 2005;11:4295–4304. Koch A, Waha A, Hartmann W, Hrychyk A, Schuller U, Waha A, Wharton KA, Jr., Fuchs SY, von Schweinitz D, Pietsch T: Elevated expression of wnt antagonists is a common event in hepatoblastomas. Clinical cancer research: an official journal of the American Association for Cancer Research 2005;11:4295–4304.
22.
Zurück zum Zitat Huang HL, Jiang Y, Wang YH, Chen T, He HJ, Liu T, Yang T, Yang LW, Chen J, Song ZQ, Yao W, Wu B, Liu G. Fbxo31 promotes cell proliferation, metastasis and invasion in lung cancer. Am J Cancer Res. 2015;5:1814–22.PubMedPubMedCentral Huang HL, Jiang Y, Wang YH, Chen T, He HJ, Liu T, Yang T, Yang LW, Chen J, Song ZQ, Yao W, Wu B, Liu G. Fbxo31 promotes cell proliferation, metastasis and invasion in lung cancer. Am J Cancer Res. 2015;5:1814–22.PubMedPubMedCentral
23.
Zurück zum Zitat Kumar R, Neilsen PM, Crawford J, McKirdy R, Lee J, Powell JA, Saif Z, Martin JM, Lombaerts M, Cornelisse CJ, Cleton-Jansen AM, Callen DF. Fbxo31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an scf complex. Cancer Res. 2005;65:11304–13.CrossRefPubMed Kumar R, Neilsen PM, Crawford J, McKirdy R, Lee J, Powell JA, Saif Z, Martin JM, Lombaerts M, Cornelisse CJ, Cleton-Jansen AM, Callen DF. Fbxo31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an scf complex. Cancer Res. 2005;65:11304–13.CrossRefPubMed
24.
Zurück zum Zitat Huang HL, Zheng WL, Zhao R, Zhang B, Ma WL. Fbxo31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma. Oncol Rep. 2010;24:715–20.CrossRefPubMed Huang HL, Zheng WL, Zhao R, Zhang B, Ma WL. Fbxo31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma. Oncol Rep. 2010;24:715–20.CrossRefPubMed
25.
Zurück zum Zitat Zhang X, Kong Y, Xu X, Xing H, Zhang Y, Han F, Li W, Yang Q, Zeng J, Jia J, Liu Z. F-box protein fbxo31 is down-regulated in gastric cancer and negatively regulated by mir-17 and mir-20a. Oncotarget. 2014;5:6178–90.CrossRefPubMedPubMedCentral Zhang X, Kong Y, Xu X, Xing H, Zhang Y, Han F, Li W, Yang Q, Zeng J, Jia J, Liu Z. F-box protein fbxo31 is down-regulated in gastric cancer and negatively regulated by mir-17 and mir-20a. Oncotarget. 2014;5:6178–90.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, Fassina A, Cordenonsi M, Piccolo S. Yap/taz incorporation in the beta-catenin destruction complex orchestrates the wnt response. Cell. 2014;158:157–70.CrossRefPubMed Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, Fassina A, Cordenonsi M, Piccolo S. Yap/taz incorporation in the beta-catenin destruction complex orchestrates the wnt response. Cell. 2014;158:157–70.CrossRefPubMed
29.
Zurück zum Zitat Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by lats and ck1 regulates yap stability through scf(beta-trcp). Genes Dev. 2010;24:72–85.CrossRefPubMedPubMedCentral Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by lats and ck1 regulates yap stability through scf(beta-trcp). Genes Dev. 2010;24:72–85.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Manfiolli AO, Maragno AL, Baqui MM, Yokoo S, Teixeira FR, Oliveira EB, Gomes MD. Fbxo25-associated nuclear domains: a novel subnuclear structure. Mol Biol Cell. 2008;19:1848–61.CrossRefPubMedPubMedCentral Manfiolli AO, Maragno AL, Baqui MM, Yokoo S, Teixeira FR, Oliveira EB, Gomes MD. Fbxo25-associated nuclear domains: a novel subnuclear structure. Mol Biol Cell. 2008;19:1848–61.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Teixeira FR, Yokoo S, Gartner CA, Manfiolli AO, Baqui MM, Assmann EM, Maragno AL, Yu H, de Lanerolle P, Kobarg J, Gygi SP, Gomes MD. Identification of fbxo25-interacting proteins using an integrated proteomics approach. Proteomics. 2010;10:2746–57.CrossRefPubMedPubMedCentral Teixeira FR, Yokoo S, Gartner CA, Manfiolli AO, Baqui MM, Assmann EM, Maragno AL, Yu H, de Lanerolle P, Kobarg J, Gygi SP, Gomes MD. Identification of fbxo25-interacting proteins using an integrated proteomics approach. Proteomics. 2010;10:2746–57.CrossRefPubMedPubMedCentral
Metadaten
Titel
FBXO25 promotes cell proliferation, invasion, and migration of NSCLC
verfasst von
Gui-Yang Jiang
Xiu-Peng Zhang
Liang Wang
Xu-Yong Lin
Juan-Han Yu
En-Hua Wang
Yong Zhang
Publikationsdatum
05.09.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5298-1

Weitere Artikel der Ausgabe 10/2016

Tumor Biology 10/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.